The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine

SARS-CoV-2 Clinical Trial

Official title:
A Single Center, Open Label Clinical Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine

Status Recruiting

Clinical Trial Summary

This study plans to enrol 1000 participants 18 years and above, with ≥10% participants ≥60 years old. According to SARS-CoV-2 vaccine vaccination history, they will be evenly divided into 2 groups, Group A and Group B. Group A: will enrol 500 participants who have received 2 doses of inactivated SARS-CoV-2 vaccine according to national immunization planning, whose last dose was given at least 6 months ago. They will be given one dose of the study vaccine (SYS6006) after enrolment. Group B: will enrol 500 participants who have received 3 doses of inactivated SARS-CoV-2 vaccine according to national immunization planning, whose last dose was given at least 6 months ago. They will be given one dose of the study vaccine (SYS6006) after enrolment. The study is devided into two stages, the first stage will enrol 200 participants with 100 in Group A and 100 in Group B. They will undergo laboratory examination, immunogenicity observation and safety observation. The first 30 participants in each group will take extra cellular immune testing; the second stage will enrol the remaining 800 participants for safety observation.

Clinical Trial Description

All participants: all the 1000 participants enrolled will undergo safety observation. Immunogenicity Subgroup: the first 100 participants enrolled in group A will be assigned to Group A1; the first 100 participants enrolled in group B will be assigned to Group B1. Blood samples will be taken from Group A1 and Group B1 participants (200 in total) for humoral immunity testing and laboratory examination. Laboratory examination include blood routine examination, urine routine test, blood biochemistry, coagulation, thyroid function, cardiac enzymes and troponin. Humoral immunity testing include serum SARS-CoV-2 neutralizing antibody detection as measured by live virus and pseudovirus assay, S1 protein specific IgG binding antibody detection as measured by ELISA. Cellular immunity Subgroup: the first 30 participants enrolled in Group A1 and Group B1 will take extra blood samples for specific cellular immune response (60 in total) as measured by ELISpot. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05492643
Study type	Interventional
Source	Zhongnan Hospital
Contact	Jianying Huang
Phone	67812668
Email	znyylcsy@126.com
Status	Recruiting
Phase	N/A
Start date	August 13, 2022
Completion date	March 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06039449` - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2	Phase 3
Completed	`NCT04512079` - FREEDOM COVID-19 Anticoagulation Strategy	Phase 4
Completed	`NCT04527471` - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19	Phase 2
Recruiting	`NCT05584202` - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants	Phase 2
Completed	`NCT04579549` - Repeat Testing for SARS-CoV-2	N/A
Active, not recruiting	`NCT05547243` - A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China	N/A
Recruiting	`NCT04747574` - Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection	Phase 1
Recruiting	`NCT04613310` - PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19)	N/A
Completed	`NCT04515147` - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19	Phase 2
Terminated	`NCT04447404` - DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury	Phase 2
Withdrawn	`NCT04388709` - Interferon Lambda Therapy for COVID-19	Phase 2
Active, not recruiting	`NCT05550142` - A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China	N/A
Completed	`NCT04620798` - Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students	N/A
Active, not recruiting	`NCT05547256` - A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China	N/A
Completed	`NCT04561102` - Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
Completed	`NCT04452604` - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed	`NCT05366322` - A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
Terminated	`NCT04958304` - Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
Completed	`NCT04526769` - Detecting SARS-CoV-2 in Tears
Completed	`NCT04690413` - NOWDx Test for the Detection of Antibodies to COVID-19	N/A